Articles

From funding to future access: Why early value planning matters in drug development

Learn how early value planning in drug development can strengthen biotech investment cases, guide evidence generation, reduce market access risk, and support future reimbursement.

Meet Acumetis at PHLEX 2026!

Attending PHLEX 2026? Meet with Acumetis to discuss your launch priorities and how we can help turn strategy into confident execution.

Why earlier commercial involvement drives smarter strategy

Explore why earlier commercial involvement, adaptive brand planning, and scenario-based decision-making can help life sciences teams respond to market change and strengthen strategy across the asset lifecycle.

From listening to action: How patient voice becomes patient insight

Download of white paper to explore how to turn patient voice into decision-ready insights that improve trial communications, launches, support, market access, and trust.

Meet Acumetis at AMCP Nexus 2026!

Meet Acumetis at AMCP Nexus 2026 and discover how we help turn evidence into stronger market access strategies.

Direct-to-employer drug models: From niche access model to channel strategy

Discover the market forces driving direct-to-employer adoption and what makes therapies strong candidates for direct commercialization.

Meet Acumetis at Fierce Pharma week 2026!

Acumetis will be participating in Fierce Pharma Week 2026 in Philadelphia, a large-scale industry event spanning commercialization, marketing, and communications. The event brings together cross-functional leaders to discuss how organizations...

Category dynamics in market access triggered by Most Favored Nation

Learn how Most Favored Nation (MFN) pricing reshapes market access, category dynamics, and global launch strategy through game theory and pricing risk.

The Greek Innovation Fund: a new framework for access to innovative therapies

Learn how Greece's Innovation Fund is advancing earlier access to innovative therapies through a new market access framework.